ISEE
Price:
$39.95
Market Cap:
$5.51B
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptida...[Read more]
Industry
Biotechnology
IPO Date
2013-09-25
Stock Exchange
NASDAQ
Ticker
ISEE
According to IVERIC bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -38.66%. This represents a change of 171.15% compared to the average of -14.26% of the last 4 quarters.
The mean historical ROE of IVERIC bio, Inc. over the last ten years is 12.34%. The current -38.66% ROE has changed -413.37% with respect to the historical average. Over the past ten years (40 quarters), ISEE's ROE was at its highest in in the September 2017 quarter at 430.94%. The ROE was at its lowest in in the September 2018 quarter at -271.70%.
Average
12.34%
Median
-32.28%
Minimum
-176.35%
Maximum
300.22%
Discovering the peaks and valleys of IVERIC bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 164.24%
Maximum Annual ROE = 300.22%
Minimum Annual Increase = -215.92%
Minimum Annual ROE = -176.35%
Year | ROE | Change |
---|---|---|
2022 | -32.86% | 3.71% |
2021 | -31.69% | -28.24% |
2020 | -44.16% | -12.11% |
2019 | -50.24% | -198.72% |
2018 | 50.89% | -83.05% |
2017 | 300.22% | 46.86% |
2016 | 204.42% | -215.92% |
2015 | -176.35% | 164.24% |
2014 | -66.74% | 121.47% |
2013 | -30.13% | -119.72% |
The current ROE of IVERIC bio, Inc. (ISEE) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-36.24%
5-year avg
-21.61%
10-year avg
12.34%
IVERIC bio, Inc.’s ROE is greater than Blueprint Medicines Corporation (-85.25%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Immunovant, Inc. (-52.07%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than 89bio, Inc. (-35.42%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Arcellx, Inc. (-12.42%), greater than Stoke Therapeutics, Inc. (-57.89%), less than Roivant Sciences Ltd. (102.72%), less than Krystal Biotech, Inc. (13.36%), greater than Prometheus Biosciences, Inc. (-21.63%), greater than Viking Therapeutics, Inc. (-15.05%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Terns Pharmaceuticals, Inc. (-39.58%), less than Reata Pharmaceuticals, Inc. (19.32%),
Company | ROE | Market cap |
---|---|---|
-85.25% | $5.47B | |
-46.15% | $161.36M | |
-30.79% | $12.60B | |
-122.70% | $1.25B | |
-52.07% | $4.98B | |
-29.56% | $1.83B | |
-95.61% | $5.30B | |
-139.02% | $5.00B | |
-35.42% | $897.06M | |
-41.05% | $782.51M | |
-12.42% | $3.83B | |
-57.89% | $773.92M | |
102.72% | $9.10B | |
13.36% | $5.29B | |
-21.63% | $9.56B | |
-15.05% | $6.00B | |
-78.24% | $794.69M | |
-39.58% | $549.60M | |
19.32% | $6.57B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IVERIC bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like IVERIC bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is IVERIC bio, Inc.'s ROE?
How is the ROE calculated for IVERIC bio, Inc. (ISEE)?
What is the highest ROE for IVERIC bio, Inc. (ISEE)?
What is the 3-year average ROE for IVERIC bio, Inc. (ISEE)?
What is the 5-year average ROE for IVERIC bio, Inc. (ISEE)?
How does the current ROE for IVERIC bio, Inc. (ISEE) compare to its historical average?